source
- FDA issues complete response letter rejecting ITM Isotope's radiopharma therapy over manufacturing concernsFDA sent a complete response letter rejecting the NDA for ITM Isotope's investigational radiopharmaceutical, citing manufacturing and third-party facility issues. The agency said there were no con…
- Former Legend Biotech chief Ying Huang named CEO of K2, targets $250 million Series A to license Asian assetsYing Huang spent the past seven years building one of the leading cancer cell‑therapy companies before stepping down as CEO of Legend Biotech. Weeks after announcing his departure, Huang has taken…